Finch Therapeutics Group, Inc.
FNCH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $19 |
| % Growth | -100% | -87.6% | -95.4% | – |
| Cost of Goods Sold | $0 | $2 | $6 | $57 |
| Gross Profit | -$0 | -$1 | -$5 | -$39 |
| % Margin | – | -1,320.6% | -539.6% | -209.1% |
| R&D Expenses | $0 | $7 | $53 | $57 |
| G&A Expenses | $0 | $27 | $38 | $21 |
| SG&A Expenses | $19 | $27 | $36 | $21 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | $1 | $0 |
| Operating Expenses | $19 | $33 | $90 | $79 |
| Operating Income | -$19 | -$34 | -$95 | -$60 |
| % Margin | – | -31,777.6% | -11,047.6% | -323.7% |
| Other Income/Exp. Net | $5 | -$44 | -$20 | $2 |
| Pre-Tax Income | -$14 | -$78 | -$115 | -$58 |
| Tax Expense | $0 | -$3 | $0 | $0 |
| Net Income | -$14 | -$75 | -$115 | -$58 |
| % Margin | – | -69,863.6% | -13,315.4% | -313.8% |
| EPS | -8.64 | -46.59 | -72.12 | -36.72 |
| % Growth | 81.5% | 35.4% | -96.4% | – |
| EPS Diluted | -8.64 | -46.59 | -72.12 | -36.72 |
| Weighted Avg Shares Out | 2 | 2 | 2 | 2 |
| Weighted Avg Shares Out Dil | 2 | 2 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $2 | $6 | $2 |
| EBITDA | -$14 | -$32 | -$83 | -$58 |
| % Margin | – | -30,357% | -9,603.6% | -311.3% |